valsartan has been researched along with Cardiomyopathies, Primary in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (37.50) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 8 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Colvin, BM; Guglin, M; Kido, K; Szymanski, TW | 1 |
| Gupta, R; Maitz, TN; Persin, K; Sundlof, DW | 1 |
| Wang, S; Zhang, F; Zhu, M | 1 |
| Butler, J; Felker, GM; Januzzi, JL; Liu, Y; Mohebi, R; Piña, IL; Prescott, MF; Solomon, SD; Ward, JH | 1 |
| Díaz-Peláez, E; Ibáñez, B; Martín-García, A; Martín-García, AC; Sánchez, PL; Sánchez-González, J | 1 |
| Cao, S; Huang, X; Jiang, X; Kang, Y; Mei, Q; Qin, D; Wu, AG; Wu, J; Yang, J; Ye, Y; Zhang, C | 1 |
| Albanez, R; Bonatto, MG; Moura, LZ; Salemi, VMC | 1 |
| Ioannou, A; Mandal, AKJ; Metaxa, S; Missouris, CG; Simon, S | 1 |
| Almufleh, A; Chan, V; Chih, S; Davies, RA; Mielniczuk, LM; Moeller, A; Stadnick, E; Zinoviev, R | 1 |
| Anwar, M; Sheppard, CE | 1 |
| Lu, J; Sun, L; Yu, XJ; Zang, WJ; Zhang, CH | 1 |
| Dai, Y; Deng, W; Su, L; Yin, YH | 1 |
| Chen, FM; Fu, GS; Wang, H; Wang, YJ | 1 |
| Akino, M; Chiba, S; Kitabatake, A; Kumamoto, H; Matsui, Y; Mikami, T; Nan, J; Okamoto, H; Onozuka, H; Shimizu, T; Sugawara, T | 1 |
| Abe, S; Aizawa, Y; Hanawa, H; Hayashi, M; Hui, L; Kashimura, T; Kato, K; Kodama, M; Nakazawa, M; Tachikawa, H; Watanabe, K; Yoshida, T | 1 |
| Ma, X; Miao, Y; Qi, TG; Sun, H; Zhang, W; Zhong, M | 1 |
1 review(s) available for valsartan and Cardiomyopathies, Primary
| Article | Year |
|---|---|
Sacubitril/Valsartan Off-Label Uses for Heart Failure.
Topics: Adult; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiomyopathies; Drug Combinations; Heart Defects, Congenital; Heart Failure; Humans; Neprilysin; Off-Label Use; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2022 |
15 other study(ies) available for valsartan and Cardiomyopathies, Primary
| Article | Year |
|---|---|
Utilization of sacubitril-valsartan for right ventricular failure in a patient with arrhythmogenic right ventricular cardiomyopathy.
Topics: Adult; Aminobutyrates; Arrhythmogenic Right Ventricular Dysplasia; Biphenyl Compounds; Cardiomyopathies; Contrast Media; Diuretics; Drug Combinations; Female; Gadolinium; Heart Failure; Humans; Valsartan | 2022 |
Preoperative Preparation With Valsartan/Sacubitril in a Patient With Cardiac Paraganglioma and Catecholamine-Induced Cardiomyopathy.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiomyopathies; Catecholamines; Drug Combinations; Heart Failure; Humans; Paraganglioma; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Heart Failure Duration and Mechanistic Efficacy of Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Cardiomyopathies; Drug Combinations; Heart Failure; Humans; Interleukin-1 Receptor-Like 1 Protein; Natriuretic Peptide, Brain; Stroke Volume; Tetrazoles; Troponin T; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2022 |
Myocardial function and structure improvement with sacubitril/valsartan in cancer therapy-induced cardiomyopathy.
Topics: Aged; Aminobutyrates; Biphenyl Compounds; Cardiomyopathies; Drug Combinations; Female; Humans; Male; Myocardial Contraction; Neoplasms; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Tandospirone enhances the anti-myocardial fibrosis effect of valsartan in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Biomarkers; Blood Pressure; Cardiomyopathies; Drug Synergism; Fibrosis; Gene Expression; Hypertension; Immunohistochemistry; Isoindoles; Male; Models, Biological; Myocardium; Piperazines; Pyrimidines; Rats; Rats, Inbred SHR; Serotonin Receptor Agonists; Smad3 Protein; Transforming Growth Factor beta; Valsartan | 2020 |
Use of sacubitril/valsartan in non-compaction cardiomyopathy: a case report.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiomyopathies; Drug Combinations; Female; Humans; Middle Aged; Stroke Volume; Valsartan | 2020 |
Comparison of the Effect of Sacubitril/Valsartan on Left Ventricular Systolic Function in Patients with Non-ischaemic and Ischaemic Cardiomyopathy.
Topics: Adult; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cardiomyopathies; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Ischemia; Neprilysin; Prospective Studies; Protease Inhibitors; Recovery of Function; Stroke Volume; Systole; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left | 2020 |
Profound Vasoplegia During Sacubitril/Valsartan Treatment After Heart Transplantation.
Topics: Aminobutyrates; Biphenyl Compounds; Cardiomyopathies; Drug Combinations; Follow-Up Studies; Heart Transplantation; Humans; Length of Stay; Male; Middle Aged; Postoperative Care; Risk Assessment; Severity of Illness Index; Tetrazoles; Treatment Outcome; Valsartan; Vasoplegia | 2018 |
The use of sacubitril/valsartan in anthracycline-induced cardiomyopathy: A mini case series.
Topics: Aged; Aminobutyrates; Anthracyclines; Biphenyl Compounds; Cardiomyopathies; Drug Combinations; Drug Therapy, Combination; Female; Humans; Retrospective Studies; Tetrazoles; Valsartan | 2019 |
Ameliorative effect of Captopril and Valsartan on an animal model of diabetic cardiomyopathy.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Cardiomyopathies; Creatine Kinase, MB Form; Diabetes Mellitus, Experimental; Female; Isoenzymes; L-Lactate Dehydrogenase; Male; Microscopy, Electron; Myocardium; Rats; Rats, Sprague-Dawley; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2008 |
[Renin-angiotensin system blocking agents reverse the myocardial hypertrophy in experimental hyperthyroid cardiomyopathy via altering intracellular calcium handling].
Topics: Animals; Calcium; Calcium Channels; Cardiomyopathies; Disease Models, Animal; Hyperthyroidism; Imidazolidines; Myocardium; Rabbits; Renin-Angiotensin System; RNA, Messenger; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Tetrazoles; Thyroxine; Valine; Valsartan | 2008 |
[The effect of valsartan and fluvastatin on the connective tissue growth factor expression in experimental diabetic cardiomyopathy].
Topics: Animals; Cardiomyopathies; Connective Tissue; Connective Tissue Growth Factor; Diabetes Mellitus, Experimental; Fatty Acids, Monounsaturated; Fluvastatin; Indoles; Male; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2009 |
VEGF-mediated angiogenesis is impaired by angiotensin type 1 receptor blockade in cardiomyopathic hamster hearts.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiomyopathies; Cricetinae; Enalapril; Endothelial Growth Factors; Intercellular Signaling Peptides and Proteins; Lymphokines; Male; Neovascularization, Pathologic; Receptor, Angiotensin, Type 1; RNA, Messenger; Tetrazoles; Time Factors; Valine; Valsartan; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Angiotensin II type 1 receptor blocker, valsartan, prevented cardiac fibrosis in rat cardiomyopathy after autoimmune myocarditis.
Topics: Angiotensin Receptor Antagonists; Animals; Autoimmune Diseases; Cardiomyopathies; Endomyocardial Fibrosis; Heart Ventricles; Male; Myocarditis; Rats; Rats, Inbred Lew; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan; Ventricular Function | 2003 |
[Activation of transforming growth factor-beta1/Smads signal pathway in diabetic cardiomyopathy and effects of valsartan thereon: experiment with rats].
Topics: Animals; Antihypertensive Agents; Blood Glucose; Blotting, Western; Cardiomyopathies; Cholesterol; Diabetes Mellitus, Experimental; Fasting; Insulin; Male; Random Allocation; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Smad Proteins; Smad2 Protein; Smad3 Protein; Smad7 Protein; Tetrazoles; Transforming Growth Factor beta1; Triglycerides; Valine; Valsartan | 2007 |